ROSETTA CAPITAL LIMITED

ROSETTA CAPITAL LIMITED is a Seed, Series A, Series B, Series C+ and secondary fund in the US, Europe and Global writing $10M–$50M checks into Healthcare, pharmaceuticals, drug-delivery and diagnostics.

Stages: Seed, Series A, Series B, Series C+, secondary
Sectors: Healthcare, pharmaceuticals, drug-delivery, diagnostics
Check size: $10M–$50M
Invests in: US-wide, Europe, Global
Round role: Follows on
Actively investing: Yes
Founded: 2001

Thesis

Rosetta Capital Limited is a UK-based venture capital firm founded in 2001, specializing in the life sciences and medical device sectors with a global investment horizon. The firm operates as a global alternative asset manager with a multi-decade track record in private markets. Their primary investment strategy centers on direct secondary transactions, offering liquidity solutions to investors and corporations, alongside primary venture investments that align with their strategic objectives. Rosetta Capital targets innovative companies in late-preclinical or clinical stages, focusing on novel therapeutics, medical devices, and diagnostics with the potential to significantly impact human lives. While headquartered in the UK, their investment approach is global, with a history of transactions in North America and Europe. The firm's average deal size ranges from $10 million to $50 million, with historical commitments in the millions of dollars. They are authorized and regulated by the Financial Conduct Authority in the UK and focus on sourcing proprietary secondary opportunities from European and North American healthcare investors and corporates.

Common questions

Does ROSETTA CAPITAL LIMITED invest at the Seed stage?

Yes. ROSETTA CAPITAL LIMITED lists Seed, Series A, Series B, Series C+ and secondary among the stages it invests in.

What check size does ROSETTA CAPITAL LIMITED write?

ROSETTA CAPITAL LIMITED writes $10M–$50M checks.

Where does ROSETTA CAPITAL LIMITED invest?

ROSETTA CAPITAL LIMITED invests in the US, Europe and Global.